Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
UK Retail Sales Rise as World Cup and Heatwave Boost Food, Pubs and Clothing 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Wall Street Slips as Oil Prices Surge 5% on Iran-Hormuz Uncertainty 
NASA's Artemis II Crew Arrives in Florida for Historic Moon Mission 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
US Yen Intervention Unlikely to Deliver Lasting Recovery, Yardeni Says 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Australian Shares Fall as Westpac Slides, Miners Gain Ahead of RBA Decision 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Yen Stabilizes After Intervention Slide as Australian Dollar Hits Eight-Week High 
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
